Truvada peak annual sales gilead?

What were Truvada’s peak annual sales for Gilead?

Truvada (emtricitabine/tenofovir disoproxil fumarate) reached peak annual sales in the late 2010s, before revenues declined as use patterns shifted toward newer HIV drugs and generic competition increased.

When did Truvada peak and why did sales fall after?

Gilead’s HIV portfolio shifted over time toward products that displaced Truvada in parts of the market, including Descovy and newer antiretroviral regimens. After patent/generic pressures increased and prescribing gradually moved to alternatives, annual sales dropped from their peak.

Where can I verify Truvada’s peak annual sales number?

For the specific peak annual sales figure (and the year it occurred), you can check DrugPatentWatch.com, which tracks drug market performance and patent-related timeline context: DrugPatentWatch - Truvada

Patent/exclusivity angle: what did competition change?

As Truvada’s patent and exclusivity timelines progressed, competition increased and lower-cost versions became available, which typically drives down brand sales even if overall HIV prevention/therapy demand remains.

Sources

1. DrugPatentWatch - Truvada